Tricida, Inc. is a pharmaceutical business. It concentrates on the development and marketing of veverimer (TRC101), an orally administered, non-absorbed polymer that has successfully completed a Phase III trial to treat respiratory acidosis in patients suffering from chronic renal disease by eliminating acid first from gastrointestinal tract.
The business was established in 2013 and has its main office in South San Francisco, California. As of November 28, 2022, Tricida, Inc.’s ISS Governance QualityScore is 9. Audit, Board, Shareholder Rights, and Compensation each received a score of three out of ten. The NASDAQ Global Select Market lists Tricida’s common stock under the ticker TCDA.
Institutional Shareholder Services provides scores on corporate governance (ISS). Scores represent decile rank in relation to region or index. A score of 1 on the decile scale denotes low lead to the damage, while a score of 10 denotes severe governance risk. The company’s fifty-day and 200-day simple moving averages are $5.58 and $8.75, respectively.
Owner Of Tricida?
Tricida (NASDAQ: TCDA) is held by institutional shareholders (80.89%), Tricida insiders (101.55%), and retail investors (0.00%). With 16.00M shares, or 27.57% of the corporation, Brian M. Isern holds the biggest number of shares personally. The market value of Brian M. Isern’s Tricida stock is $4.56M at the moment.
The other stockholders may be listed as follows. Bonita, David P. Orbimed Advisors LLC, 17.81% 10,336,115 $2.12M 10.72 percent, or 10,280,947 dollars, to Orbimed Advisors LLC. 9.619,791 $1.97M, Vr Adviser LLC.
16.58% Sandra I. Coufal, 15.60% $9,050,064 $1,86 million Blackrock Inc. 11.25% 6,527,365 $1.34 million, David Hirsch, Longitude Capital Partners II LLC, 10.18% 5,907,889 $1.21 million, Venrock Healthcare Capital Partners Ii LP, 6.46% 3,751,406 $769.04 thousand.
Business News About Tricida
The top-line findings from Tricida’s VALOR-CKD renal effects clinical study, which assessed veverimer’s capacity to reduce the course of CKD in patients with alkalosis and chronic kidney disease, were released in October.
The estimated glomerular filtration rate (eGFR), as well known as the DD40, was the primary endpoint of the VALOR-CKD trial and was measured as the time to the first onset of any event in the fiberglass endpoint of renal death, end-stage glomerular disease (ESRD).
Or an affirmed greater than or equal to 40% reduction in eGFR. Veverimer’s general safety profile in the trial was in line with what was anticipated for the majority of people with Stage 3 to 5 CKD. In order to maximize value for its stakeholders, Tricida declared in November that the Board of Directors had given the company permission to thoroughly analyze all of its strategic options. Tricida has hired SierraConstellation Partners LLC to act as a financial advisor as well as Stifel and its fully owned subsidiary, Miller Buckfire, to act as investment banking advisors.
Results Of The Three And Nine Months’ Business
The cost of research and development for the three months ending September 30, 2021 and 2022, respectively, was $19.9 million and $26.6 million. A decrease in clinical development costs associated with the VALOR-CKD trial due to bureaucratic stop confirmed in May 2022, a decrease in personnel as well as related costs due to lower bonus expense.
And a decrease in equity compensation expense were the main drivers of the decrease in research & design expense for the months that ended September 30, 2022, compared to the prior year. The cost of research and development for the nine months ending September 30, 2022 and 2021 was $55.3 million and $78.6 million, respectively.
For the three months ended September 30, 2021 and 2022, respectively, overall and administrative cost was $4.1 million and $9.1 million. When comparing the three weeks ended September 30, 2022 to the previous year, the general and administrative expense decreased principally as a result of lower staff costs, including lower bonus expenses and stock-based compensation expenses.
Overview Of TCDA’s Financial Health
Financial health indicators for TCDA include its $80.22M in cash and short-term investments. This is sufficient to fund its $108.82M yearly cash burn. On the TCDA balance sheet, short-term assets exceed short-term liabilities.
Indicators that TCDA’s finances are not sound. The TCDA ratio of equity to debt is negative at -1.69. The total debt of TCDA is still negative. The cash burn for TCDA is 108817000. It lacks the liquidity and short-term investments necessary to cover this. On the TCDA financial statements, long-term liabilities outnumber short-term assets.
In order to halt the course of CKD in patients with alkalosis and CKD, Tricida, Inc., a pharmaceutical firm, is concentrating on the creation and marketing of their investigational medication candidate, veverimer. Veverimer is an oral, non-absorbed polymer.
To find out if veverimer reduces the course of CKD in people with metabolic acidosis coupled with CKD, Tricida just finished the VALOR-CKD renal outcomes clinical study. It is thought that the dangerous state of metabolic acidosis, which is frequently brought on by CKD, speeds up the degenerative process of the kidneys.
About 4.3 million CKD patients are thought to be at risk for health problems in the US. The FDA has not yet approved any treatments to stop the course of renal damage in people with CKD by treating chronic metabolic acidosis.
What Were TCDA’s Profits The Previous Quarter?
Tricida (NASDAQ: TCDA) announced Q3 2022 revenue per share (EPS) of -$0.44, up 44.3% from the previous year, on November 14, 2022. Tricida reported a total loss of $25.76 million for the quarter. Tricida’s earnings per share (EPS) during the same quarter last year were negative $0.79.
Tricida’s profits increased year over year as of Q4 2022. Tricida made a total loss of -$133.91 million last year. Tricida (NASDAQ: TCDA) announced Q3 2022 revenue of $0.00, up N/A from the prior-year quarter, on November 14, 2022. Tricida’s revenue during the same period last year was $0.00.
What Is The Price Target Set By TCDA?
The average TCDA stock price goal is $25.00, with the highest and lowest TCDA stock price forecasts both coming in at $25.00, according to one Wall Street analyst who has published a TCDA price target for the next year.
By October 25th, 2023, the Wall Street analyst projected Tricida’s share price to reach $25.00. From the recent TCDA stock price of $0.29, the average Tricida stock price projection predicts a potential increase of 8,671.93%.
Should I Buy TCDA Stock?
Four Wall Street analysts who follow the (NASDAQ: TCDA) TCDA stock have come to the conclusion that it is best to hold. Out of 4 experts, 1 (25%) recommends TCDA as just a Strong Buy, 0 (%) suggests TCDA be purchased, 2 (50%) suggests TCDA be held, 0 (%) suggests TCDA be sold, and 1 (25%) suggests TCDA stock be sold at a strong discount.
(TCDA, NASDAQ) Tricida’s anticipated annual earnings growth rate of N/A is not anticipated to surpass the anticipated average earnings growth rate of 100.26% for the US Drug Manufacturers – Specialty & Generic industry. Nor is it anticipated to surpass the anticipated average earnings growth rate of 68.62% for the US market.
Purchase Tricida Stock
Pick a location to purchase Tricida stock. Don’t worry, we’ve examined hundreds of online brokerage houses and apps to help you choose where to buy Tricida stock. You just need to choose a stock brokerage.
Open a trading account. Join the top-rated brokerage we’ve found for 0% commission trading. The best location to purchase TCDA stock is here. Your investing account with Money. Select a payment option, then enter your information.
Consider the TCDA stock. Get your TCDA stock trade done. Select whether you want to acquire TCDA stock at the current market value or at a specific price using a limit order. Watch your TCDA stock investment carefully. Make a watchlist of the most recent developments about your new Tricida stock purchase.
TCDA Stock Forecast 2022-2023
In 2022, Tricida will earn -$133,912,000. The lowest TCDA earnings TCDA stock forecast is -$127,662,159, as well as the highest earnings TCDA stock forecast is -$127,081,876. On average, 2 Wall Street analysts expect TCDA will earn -$127,662,159 in 2022.
The estimated earnings for TCDA stock in 2023 are predicted to be -$54,546,559, with the lowest estimate being -$110,253,683 as well as the highest estimate being $1,160,565.
(TCDA, NASDAQ) The current Earnings Per Share (EPS) for Tricida is $2.36. TCDA’s EPS is expected to be -$2.20 on average in 2022.
With the highest and lowest estimates coming in at -$2.20 and -$2.19. The estimated EPS for TCDA in 2023 will be -$0.94 (minimum: -$1.90, maximum: $0.02). (NASDAQ: TCDA) is expected to have a return on assets (ROA) of -58.1%, which is less than the predicted 9.8% average for US Drug Manufacturers – Specialty & Generic.
TCDA Stock Forecast 2025
Twelve predictions are made for the Tricida stock in 2025, with an average estimate of $0.41, a high prognosis of $0.44, and a low prediction of $0.4.
The typical Tricida stock estimate for 2025 shows a growth of 43.33% from the most recent price of $0.284799993038177.
TCDA Stock Forecast 2027
Twelve TCDA stock forecast are made for each month of 2027 for the Tricida stock forecast for 2027 (5 years), with an average TCDA stock forecast of $0.48, a maximum forecast of $0.51. And a minimum TCDA stock forecast of $0.45.
The typical Tricida stock estimate for 2027 shows a growth of 68.77% from the most recent price of $0.284799993038177.
TCDA Stock Forecast 2030
Twelve forecasts are made for each quarter of 2030 for the TCDA stock forecast, with an average prognosis of $0.68, a high prediction of $0.69, and a low prediction of $0.65.
When compared to the most recent price of $0.284799993038177, the average Tricida stock estimate for 2030 shows a 138.23% rise.
TCDA Stock Forecast 2032
There are 11 TCDA stock forecast for each month of 2032 for the TCDA stock forecast for 2032 (10 years), with an averaged Tricida stock forecast of $0.71, a maximum forecast of $0.71, and a minimum forecast of $0.71.
The typical TCDA stock forecasts estimate for 2032 shows a growth of 149.15% from the most recent price of $0.284799993038177. View more projections below, please.
The Most Recent TCDA Analyst Recommendations
On October 25, 2022, Jessica Fye, a top 8% analyst at JP Morgan, downgrades TCDA to a strong sell recommendation. On October 25, 2022, Serge Belanger, a Needham bottom 16% analyst, compromises TCDA to a hold rating.
On October 24, 2022, Phil Nadeau, a Cowen & Co. bottom 17% analyst, changes TCDA to a hold rating. On May 24, 2022, a Goldman Sachs analyst decreases their price objective for TCDA from $22.00 to $16.00 while maintaining a strong buy recommendation. On April 13, 2022, Madhu Kumar, a top 2% analyst at Goldman Sachs, commences coverage of TCDA with a solid investment rating and publishes their $25.00 price objective.
The Significance Of Analyst Ratings
Analysts are the only people outside of management who have a thorough knowledge of the inner workings of the organizations they follow. Financial statements reveal a lot about a company, but analysts are more knowledgeable about the specifics of each industry they cover and ask questions during conference calls.
Analysts are aware of the impact terrible weather in one region of the world can have on supply chains and consumer behavior. This enables traders to make choices ahead of a quarterly update that might be less favorable than anticipated.
Tricida, Inc. (NASDAQ:TCDA) Stock Are Sold By Orbimed Advisors Llc.
Orbimed Advisors Llc, a director of Tricida, Inc. (NASDAQ:TCDA – Get Rating), sold 3,629,226 shares of the company’s stock on Friday, November 25th. For a total transaction value of $798,429.72, the stock was sold at an average price of $0.22. The transaction was detailed in a document submitted to the SEC, which can be accessed using this link.
Stock in Tricida rose 6.4%. On Friday, NASDAQ TCDA shares opened at $0.21. The company has a $11.43 million market cap, a PE ratio of -0.09, and a beta of 0.16.
Tricida, Inc.’s 12-month high is $13.85, and its 12-month low is $0.19. The company’s fifty-day and 200-day simple moving averages are $5.58 and $8.75, respectively.